BridgeMD
New treatment option for Epiretinal Membrane
Official title (CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
ClinicalTrials.gov ID: NCT07680244
What this study is testing
- What it's testing
- This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Able and willing to make the required study visits.
- Able and willing to give written informed consent and follow study instructions.
- Able and willing to complete ophthalmic imaging.
- Adults 18 years of age or older. The subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula...
- people with Disruption of the vitreoretinal interface (VRI)
You likely can't join if
- Inability to undergo the required tests.
- Unable to give consent or follow study instructions.
- Inability to fixate that precludes obtaining acceptable macula scans in the study eye.
- Visudyne (verteporfin) injection within the last 48 hours in the study eye.
- Pilocarpine or Vuity use within the last 24 hours in the study eye.
- Dense media opacity precluding adequate visualization of the retina in the study eye.
See the full eligibility criteria
- Able and willing to make the required study visits.
- Able and willing to give written informed consent and follow study instructions.
- Able and willing to complete ophthalmic imaging.
- Adults 18 years of age or older. The subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area): Group A 1\. people with absence of macular abnormalities Group B
- people with Disruption of the vitreoretinal interface (VRI)
- people with Intraretinal hyporeflective space (IRHS)
- people with Subretinal hyporeflective space (SRHS)
- people with IS/OS (Ellipsoid Zone) disruption
- people with Retinal Pigment Epithelium (RPE) elevation
- people with Retinal Pigment Epithelium (RPE) atrophy
- Other abnormalities
- Inability to undergo the required tests.
- Unable to give consent or follow study instructions.
- Inability to fixate that precludes obtaining acceptable macula scans in the study eye.
- Visudyne (verteporfin) injection within the last 48 hours in the study eye.
- Pilocarpine or Vuity use within the last 24 hours in the study eye.
- Dense media opacity precluding adequate visualization of the retina in the study eye.
- Vitreous floaters that preclude obtaining acceptable scans in the study eye.
The study team makes the final eligibility decision.
Where it's taking place
- Tucson, Arizona, United States
- Mountain View, California, United States
- San Francisco, California, United States
- Fort Lauderdale, Florida, United States
- Portland, Maine, United States
- Kansas City, Missouri, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tucson, Arizona, United States; Mountain View, California, United States; San Francisco, California, United States; Fort Lauderdale, Florida, United States; Portland, Maine, United States; Kansas City, Missouri, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.